Supernus Pharma (NASDAQ: SUPN) reported Q1 EPS of $0.34, $0.13 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $85.5 million versus the consensus estimate of $103.87 million.

Financial guidance reaffirmed

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.